论文部分内容阅读
目的探讨骨碎补总黄酮联合阿法骨化醇治疗骨质疏松症的疗效。方法选取2013年1月—2014年12月在保定市第二医院接受治疗的骨质疏松患者102例,随机分为试验组(50例)和对照组(52例)。对照组口服含钙600 mg和维生素D 125 IU的钙尔奇D片,1次/d。试验组口服骨碎补总黄酮,饭后用温开水送服,1粒/次,3次/d;口服阿法骨化醇0.5μg/d。两组疗程均为1年。利用DXA仪测定治疗前后患者的L2、L3、L4,华氏三角区、股骨粗隆、左股骨颈的骨密度(BMD)以及血钙浓度和VAS疼痛视觉评分。采用SPSS18.0软件对所得数据进行统计分析,计量资料应用t检验;计数资料应用χ2检验,P<0.05为差异有统计学意义。结果试验组总有效率为76.00%,明显优于对照组的总有效率53.85%,差异有统计学意义(P<0.05)。试验组治疗后L2、L3、L4、华氏三角区、股骨颈和股骨粗隆的平均骨密度分别为(0.754±0.101)、(0.782±0.111)、(0.809±0.126)、(0.727±0.146)、(0.721±0.130)、(0.846±0.148)g/cm2,明显优于对照组治疗后的(0.621±0.108)、(0.701±0.109)、(0.756±0.106)、(0.672±0.108)、(0.665±0.120)、(0.785±0.142)g/cm2,差异均有统计学意义(P<0.05);试验组治疗后平均血钙浓度为(2.65±0.22)mg/dl,高于对照组治疗后的(2.42±0.17)mg/dl,差异有统计学意义(P<0.05);VAS疼痛视觉评分试验组治疗后平均为(2.91±0.73)分,低于对照组治疗后的(4.32±0.96)分,差异有统计学意义(P<0.05)。两组均无明显不良反应。结论骨碎补总黄酮联合阿法骨化醇治疗骨质疏松症的疗效较好,不良反应少,安全性高。
Objective To investigate the curative effect of osteoporosis total flavonoids combined with alfacalciferol on osteoporosis. Methods A total of 102 patients with osteoporosis treated in the Second Hospital of Baoding from January 2013 to December 2014 were randomly divided into two groups: experimental group (50 cases) and control group (52 cases). Control group oral calcium 600 mg and vitamin D 125 IU of Calcium D tablets, 1 / d. The experimental group was orally administered with total flavonoids of Rhizoma Drynariae, and was served with warm water after a meal, once a day / time for 3 times / d. Oral alfacalcidol 0.5μg / d was administered orally. Two courses of treatment are 1 year. The DXA was used to measure the patient’s L2, L3, L4, Fahrenheit triangle, femoral trochanter, left femoral neck BMD, and serum calcium concentration and VAS pain visual score before and after treatment. SPSS18.0 software was used for statistical analysis of the data obtained, measurement data using t test; count data usingχ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate of the experimental group was 76.00%, which was significantly better than that of the control group (53.85%), the difference was statistically significant (P <0.05). The average BMD of L2, L3, L4, Fahrenheit triangle, femoral neck and femoral tuberosity were (0.754 ± 0.101), (0.782 ± 0.111), (0.809 ± 0.126) and (0.727 ± 0.146) (0.721 ± 0.130) and (0.846 ± 0.148) g / cm2, respectively, which were significantly better than that of the control group after treatment (0.621 ± 0.108, 0.701 ± 0.109, 0.756 ± 0.106, 0.672 ± 0.108, 0.665 ± 0.120) and (0.785 ± 0.142) g / cm2, respectively, with statistical significance (P <0.05). The mean serum calcium concentration of the experimental group after treatment was (2.65 ± 0.22) mg / dl, which was higher than that of the control group (2.42 ± 0.17) mg / dl, the difference was statistically significant (P <0.05); VAS pain visual score test group averaged (2.91 ± 0.73) points after treatment, which was lower than that of the control group (4.32 ± 0.96) The difference was statistically significant (P <0.05). No significant adverse reactions in both groups. Conclusion Drynaria total flavonoids combined with alfacalcidol treatment of osteoporosis better curative effect, less adverse reactions, high safety.